CWS
NMTR

Cypress Wealth Services’s 9 Meters Biopharma NMTR Stock Holding History

Cypress Wealth Services’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,275
Closed -$21K – 534
2020
Q3 		$21K Buy
+1,275
New +$15.5K 0.01% 265

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cypress Wealth Services's NMTR Position: Q2 2021 in Review

Cypress Wealth Services sold out of 9 Meters Biopharma (NMTR) in Q2 2021, closing a stake of 1,275 shares — an estimated $30K sold.

Cypress Wealth Services first reported a position in NMTR in Q2 2020 and held it in 3 quarters. The position peaked at $30K in Q1 2021. 99 funds tracked by Wall St. Rank hold NMTR as of Q2 2021.

  • Cypress Wealth Services reported no remaining 9 Meters Biopharma position as of Q2 2021 after selling out during the quarter.
  • Cypress Wealth Services sold 1,275 9 Meters Biopharma shares in Q2 2021, an estimated $30K.
  • Cypress Wealth Services first reported a position in 9 Meters Biopharma in Q2 2020 and held it in 3 quarters.
  • Cypress Wealth Services's 9 Meters Biopharma position peaked at $30K in Q1 2021.
  • 99 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2021.

Based on Cypress Wealth Services's 13F filing for Q2 2021, filed 14 Jul 2021.